Advancing Tobacco Use Treatment for African American Smokers

• Status: Completed
• Trial end date: 2018-07-12
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine whether or not providing Chantix (varenicline) will help African American smokers quit smoking.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Lisa Sanderson Cox, PhD
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: Varenicline

Criteria

Inclusion Criteria:

• Self-identified African American

• Smokes ≥ 1 cigarette per day (cpd)

• Smoke on ≥ 25 days of the past 30 days

• Functioning telephone

• Interested in quitting smoking

• Interested in taking 3 months of varenicline

• Willing to complete all study visits

Exclusion Criteria:

• Renal impairment

• Evidence or history of clinically significant allergic reactions to varenicline

• A cardiovascular event in the past month

• History of alcohol or drug dependence in the past year

• Major depressive disorder in the last year requiring treatment

• History of panic disorder, psychosis, bipolar disorder, or eating disorders

• Use of tobacco products other than cigarettes in past 30 days

• Use of pharmacotherapy in the month prior to enrollment, including prior use of varenicline

• Pregnant, contemplating getting pregnant, or breastfeeding

• Plans to move from Kansas City during the treatment and follow-up phase

• Another household member enrolled in the study

• Evidence of current severe major depressive disorder or suicidal ideation